Are Vivanza Biosciences Ltd latest results good or bad?

Vivanza Biosciences Ltd's latest financial results for Q4 FY26 reveal significant operational challenges despite remarkable year-on-year revenue growth. The company reported net sales of ₹6.36 crores, reflecting an extraordinary increase of 1,225.00% compared to the same quarter last year. However, this figure represents a substantial sequential decline of 85.94% from ₹45.25 crores in Q3 FY26, raising concerns about revenue volatility and sustainability. The net profit for the quarter was a loss of ₹0.45 crores, marking a 325.00% decline from the previous quarter and a 55.00% decline year-on-year. This loss indicates that the company is currently loss-making on a trailing twelve-month basis, which has led to questions regarding its ability to achieve sustainable profitability. The operating profit before depreciation, interest, tax, and other income (PBDIT) turned negative at -₹0.24 crores, resulting in an operating margin of -3.77%, a sharp decline from the positive margin of 0.46% in Q3 FY26. This deterioration in margins, coupled with high financial leverage indicated by a net debt to equity ratio of 2.07, underscores the financial risks the company faces. Despite the impressive year-on-year revenue growth, the company’s performance metrics reveal a troubling trend of inconsistent profitability and operational instability. The nine-month performance for FY26 shows cumulative net sales of ₹109.55 crores, a staggering increase from ₹4.48 crores in the same period last year. However, the net profit for this period was only ₹0.31 crores, further emphasizing the challenges in translating revenue growth into consistent profits. In light of these results, Vivanza Biosciences experienced an adjustment in its evaluation, reflecting the complexities of its financial situation. Investors are advised to closely monitor the company's ability to stabilize operations and convert its revenue growth into sustainable profitability moving forward.